Medifast Reports Steep Revenue Decline, Net Loss, and Weak 2026 Outlook Amidst GLP-1 Headwinds

summarizeSummary

Medifast announced a significant 36.9% revenue decrease and a net loss for Q4 2025, along with a weak outlook for 2026, citing challenges from GLP-1 medications.

check_boxKey Events

• Q4 2025 Revenue Decline

  Revenue decreased 36.9% year-over-year to $75.1 million for the fourth quarter of 2025.

• Shift to Net Loss

  The company reported a net loss of $18.1 million, or $1.65 per diluted share, for Q4 2025, compared to a net income in the prior year. This includes a $12.1 million non-cash valuation allowance on deferred tax assets.

• Weak 2026 Guidance

  Medifast projects full year 2026 revenue in the range of $270 million to $300 million, a further decline from 2025, with an expected loss per share ranging from $1.55 to $2.75.

• GLP-1 Impact Cited

  Management explicitly attributed the decrease in active earning coaches and overall revenue to "rapid adoption of GLP-1 medications for weight loss," indicating a significant competitive headwind.

auto_awesomeAnalysis

Medifast's latest earnings report reveals a company under severe pressure, with substantial declines in both quarterly and full-year revenue and a shift from profitability to significant losses. The explicit mention of GLP-1 medications as a primary driver for the decrease in active coaches and overall revenue highlights a fundamental challenge to its business model. While the company is attempting a strategic pivot towards "metabolic health" and saw a slight increase in revenue per coach, the forward guidance for 2026 indicates continued revenue contraction and unprofitability. This report signals ongoing operational difficulties and a challenging competitive landscape, likely leading to further investor concern, especially with the stock already trading near its 52-week low.